Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Femara (Letrozole) Plus Ribociclib (LEE011) or Placebo as Neo-adjuvant Endocrine Therapy for Women With ER-positive, HER2-negative Early Breast Cancer

NCT02712723 is registered in ClinicalTrials.gov with Qamar Khan as lead sponsor.

NCT NCT02712723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02712723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Femara (Letrozole) Plus Ribociclib (LEE011) or Placebo as Neo-adjuvant Endocrine Therapy for Women With ER-positive, HER2-negative Early Breast Cancer
Lead sponsor
Qamar Khan
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 29, 2016
Completion date
December 31, 2026
Enrollment
121 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer